Enhanced Stability Ready-to-Use Injectables of Melphalan

A novel approach to stabilize melphalan formulations, providing improved stability, safety, and efficiency in ready-to-use injectables for cancer treatment.

The original patent, 'Ready to use injectable formulations of melphalan and processes for preparation thereof', provides a foundation for stable melphalan formulations. However, the existing formulation still faces limitations in terms of degradation and stability. The new inventive concept addresses these limitations by introducing pH-adjusting agents, optimized solvent systems, and antimicrobial preservatives to enhance stability and shelf life.

The new inventive concept comprises a system for stabilizing melphalan formulations, a method for preparing ready-to-use injectable formulations, a melphalan formulation kit, and a process for preparing stable ready-to-use injectable formulations. These innovations involve the use of pH-adjusting agents to maintain a pH range of 5.0 to 7.0, solvent systems comprising polyethylene glycol, ethanol, and water, and preservatives such as benzyl alcohol and phenol. These components work synergistically to reduce degradation, enhance stability, and provide antimicrobial properties.

The new claims introduce novel pH-adjusting agents, optimized solvent systems, and antimicrobial preservatives, which are not present in the original patent. These innovations provide an inventive step over the existing formulation, enabling improved stability, safety, and efficiency in ready-to-use injectables.

Alternative embodiments may include using different pH-adjusting agents, solvent systems, or preservatives. Variations of the melphalan formulation kit could include different packaging configurations or reconstitution methods. Additionally, the inventive concept could be adapted for use with other pharmaceutical compounds or in different therapeutic areas.

The enhanced stability ready-to-use injectables of melphalan have significant commercial potential in the cancer treatment market. The improved stability and shelf life of these formulations can reduce costs associated with formulation preparation, storage, and transportation, while also enhancing patient safety and convenience. The target industries include pharmaceutical companies, hospitals, and cancer treatment centers.